South Korea-based drug production company LOTTE BIOLOGICS announced on Monday that it has entered into a late-stage to commercial contract manufacturing partnership with a US-based global biopharmaceutical company.

The partnership covers a late-stage Phase 3 programme that is advancing into multiple new indications, and extends to commercial supply following potential regulatory approvals.

LOTTE BIOLOGICS said that by aligning with its partner's meaningful pipeline expansion into new therapeutic areas, it will be playing a pivotal role in supporting patient access to innovative medicines.

In accordance with confidentiality obligations, the client's identity has not been disclosed. The term of the contract extends until the middle of 2030.